Clinical Trial Update: Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for capmatinib in non-small cell lung cancer with MET exon 14 skipping mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Cancer, Lung Cancer Metastatic | Phase 2 | Status: UNKNOWN